Cadrenal Therapeutics, Inc. (CVKD)
(Delayed Data from NSDQ)
$0.43 USD
+0.02 (4.69%)
Updated Aug 8, 2024 03:59 PM ET
After-Market: $0.43 0.00 (-0.72%) 6:28 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Cadrenal Therapeutics, Inc. [CVKD]
Reports for Purchase
Showing records 1 - 4 ( 4 total )
Company: Cadrenal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Potential Implications of Abbott''s ARIES-HM3 Trial for Cadrenal and Tecarfarin
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cadrenal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Phase 3 ACTOR AF Trial Gears Up for 2H24 Launch Pending Funding Satisfaction
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cadrenal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Phase 3 ACTOR AF Trial to Begin in 2H24 as We Await FDA Guidance on Primary Endpoint
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cadrenal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Time to Bid Adieu to Warfarin for Better Anticoagulation Solutions; Initiating at Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
|